New investment in Capitainer
We Venture Capital lead Series A round of 6.7 m EUR in Capitainer AB, a Swedish start-up developing point of need diagnostics microsampling solutions. We Venture Capital invest alongside Sciety and Sciety Venture Partners.
The new investment enables Capitainer to increase efforts in sales and production. During the next 18 months, Capitainer will build out production capacity, initiate key collaborations and solidify sales of its microsampling products in EU and US. The investment is the first scale-up round after years of successful product development.
We are very impressed by the product performance and what the Capitainer team has achieved the last few years. The product portfolio is disruptive and innovative and demonstrate very solid data. We look forward to supporting Capitainer on their future journey.
Louise Warme, Head of We Venture Capital
The company operations in Sweden today and are scaling up by building an agent and distribution network in Europe, as well as sales channels in the US.
This investment enables us to focus our sales and marketing efforts in EU and in US. We are very happy to work with We Venture Capital who will be an active investor for Capitainer. The timing is perfect as we are now expanding sales due to the progress we have had in 2023 in Diabetes monitoring, self-sampling of Kidney transplanted patients and solutions for Drugs of Abuse and Heavy Metal screening.
Christopher Aulin, CEO of Capitainer
About We Venture Capital
We Venture Capital is a specialized fund investing in diagnostics, as well as tools and digital solutions in the diagnostics area. Being the corporate investment arm of Werfen, a worldwide leader in specialized diagnostics, We Venture Capital is an active investor, leveraging the network and knowledge from Werfen to the benefit of our investments.
We invest in and partner with early-stage startups close to market entry or early scale-ups, working close with our portfolio to support their growth over time. We are firm believers of technical advancement as a means to improve patient outcomes and revolutionize healthcare.
About Capitainer
Capitainer AB is a Swedish MedTech company that develops and sells patient-centric solutions for self-sampling of blood, plasma, and urine. Founded in 2016, Capitainer has developed unique technologies for collecting and drying exact volumes of fluid within easy-to-use sampling cards. These cards may be sent as standard post to relevant testing laboratories, thus bypassing the need for cold chain logistics and specialised packaging. Capitainer’s products are market-leading with respect to precision and accuracy, with demonstrated equal performance to established pipetting methods. The products are applicable within several market segments, including but not limited to, clinical biomarkers, therapeutic drug monitoring, genomics, drug abuse and doping testing, and R&D and clinical studies.
For more information, please contact:
Christopher Aulin, CEO
Phone: +46 (0)708 977577
Email: christopher.aulin@capitainer.com